Market Research Logo

Global Duchenne Muscular Dystrophy Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Global Duchenne Muscular Dystrophy Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Duchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Scope of the Report:
This report focuses on the Duchenne Muscular Dystrophy in global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, types and applications.
Market Segment by Manufacturers, this report covers
PTC Therapeutics
Sarepta Therapeutics
Bristol-Myers Squibb
ITALFARMACO
BioMarin
Daiichi Sankyo
Solid Biosciences
Summit Therapeutics
FibroGen
NS Pharma
Pfizer
ReveraGen BioPharma
Wave Life
Genethon
Santhera Pharmaceuticals

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Deflazacort
Prednisone
Others

Market Segment by Applications, can be divided into
Male
Female

There are 15 Chapters to deeply display the global Duchenne Muscular Dystrophy market.

Chapter 1, to describe Duchenne Muscular Dystrophy Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Duchenne Muscular Dystrophy, with sales, revenue, and price of Duchenne Muscular Dystrophy, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Duchenne Muscular Dystrophy, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Duchenne Muscular Dystrophy market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Duchenne Muscular Dystrophy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source


1 Market Overview
1.1 Duchenne Muscular Dystrophy Introduction
1.2 Market Analysis by Type
1.2.1 Deflazacort
1.2.2 Prednisone
1.2.3 Others
1.3 Market Analysis by Applications
1.3.1 Male
1.3.2 Female
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market Status and Outlook (2013-2023)
1.4.1.2 Canada Market Status and Outlook (2013-2023)
1.4.1.3 Mexico Market Status and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market Status and Outlook (2013-2023)
1.4.2.2 France Market Status and Outlook (2013-2023)
1.4.2.3 UK Market Status and Outlook (2013-2023)
1.4.2.4 Russia Market Status and Outlook (2013-2023)
1.4.2.5 Italy Market Status and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market Status and Outlook (2013-2023)
1.4.3.2 Japan Market Status and Outlook (2013-2023)
1.4.3.3 Korea Market Status and Outlook (2013-2023)
1.4.3.4 India Market Status and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market Status and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market Status and Outlook (2013-2023)
1.4.4.2 Egypt Market Status and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market Status and Outlook (2013-2023)
1.4.4.4 South Africa Market Status and Outlook (2013-2023)
1.4.4.5 Nigeria Market Status and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 PTC Therapeutics
2.1.1 Business Overview
2.1.2 Duchenne Muscular Dystrophy Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sarepta Therapeutics
2.2.1 Business Overview
2.2.2 Duchenne Muscular Dystrophy Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers Squibb
2.3.1 Business Overview
2.3.2 Duchenne Muscular Dystrophy Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 ITALFARMACO
2.4.1 Business Overview
2.4.2 Duchenne Muscular Dystrophy Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 ITALFARMACO Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 BioMarin
2.5.1 Business Overview
2.5.2 Duchenne Muscular Dystrophy Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 BioMarin Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Daiichi Sankyo
2.6.1 Business Overview
2.6.2 Duchenne Muscular Dystrophy Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Daiichi Sankyo Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Solid Biosciences
2.7.1 Business Overview
2.7.2 Duchenne Muscular Dystrophy Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Solid Biosciences Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Summit Therapeutics
2.8.1 Business Overview
2.8.2 Duchenne Muscular Dystrophy Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Summit Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 FibroGen
2.9.1 Business Overview
2.9.2 Duchenne Muscular Dystrophy Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 FibroGen Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 NS Pharma
2.10.1 Business Overview
2.10.2 Duchenne Muscular Dystrophy Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 NS Pharma Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Pfizer
2.11.1 Business Overview
2.11.2 Duchenne Muscular Dystrophy Type and Applications
2.11.2.1 Type 1
2.11.2.2 Type 2
2.11.3 Pfizer Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 ReveraGen BioPharma
2.12.1 Business Overview
2.12.2 Duchenne Muscular Dystrophy Type and Applications
2.12.2.1 Type 1
2.12.2.2 Type 2
2.12.3 ReveraGen BioPharma Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Wave Life
2.13.1 Business Overview
2.13.2 Duchenne Muscular Dystrophy Type and Applications
2.13.2.1 Type 1
2.13.2.2 Type 2
2.13.3 Wave Life Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Genethon
2.14.1 Business Overview
2.14.2 Duchenne Muscular Dystrophy Type and Applications
2.14.2.1 Type 1
2.14.2.2 Type 2
2.14.3 Genethon Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Santhera Pharmaceuticals
2.15.1 Business Overview
2.15.2 Duchenne Muscular Dystrophy Type and Applications
2.15.2.1 Type 1
2.15.2.2 Type 2
2.15.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Duchenne Muscular Dystrophy Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Duchenne Muscular Dystrophy Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Duchenne Muscular Dystrophy Manufacturer Market Share
3.3.2 Top 6 Duchenne Muscular Dystrophy Manufacturer Market Share
3.4 Market Competition Trend
4 Global Duchenne Muscular Dystrophy Market Analysis by Regions
4.1 Global Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Regions
4.1.1 Global Duchenne Muscular Dystrophy Sales and Market Share by Regions (2013-2018)
4.1.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Regions (2013-2018)
4.2 North America Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
4.3 Europe Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
4.5 South America Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
5 North America Duchenne Muscular Dystrophy by Countries
5.1 North America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
5.1.1 North America Duchenne Muscular Dystrophy Sales and Market Share by Countries (2013-2018)
5.1.2 North America Duchenne Muscular Dystrophy Revenue and Market Share by Countries (2013-2018)
5.2 United States Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
5.3 Canada Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
5.4 Mexico Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6 Europe Duchenne Muscular Dystrophy by Countries
6.1 Europe Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
6.1.1 Europe Duchenne Muscular Dystrophy Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Duchenne Muscular Dystrophy Revenue and Market Share by Countries (2013-2018)
6.2 Germany Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.3 UK Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.4 France Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.5 Russia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.6 Italy Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7 Asia-Pacific Duchenne Muscular Dystrophy by Countries
7.1 Asia-Pacific Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Duchenne Muscular Dystrophy Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue and Market Share by Countries (2013-2018)
7.2 China Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.3 Japan Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.4 Korea Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.5 India Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
8 South America Duchenne Muscular Dystrophy by Countries
8.1 South America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
8.1.1 South America Duchenne Muscular Dystrophy Sales and Market Share by Countries (2013-2018)
8.1.2 South America Duchenne Muscular Dystrophy Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
8.3 Argentina Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
8.4 Colombia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9 Middle East and Africa Duchenne Muscular Dystrophy by Countries
9.1 Middle East and Africa Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Duchenne Muscular Dystrophy Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.3 UAE Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.4 Egypt Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.5 Nigeria Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.6 South Africa Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
10 Global Duchenne Muscular Dystrophy Market Segment by Type
10.1 Global Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Duchenne Muscular Dystrophy Sales and Market Share by Type (2013-2018)
10.1.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2013-2018)
10.2 Deflazacort Sales Growth and Price
10.2.1 Global Deflazacort Sales Growth (2013-2018)
10.2.2 Global Deflazacort Price (2013-2018)
10.3 Prednisone Sales Growth and Price
10.3.1 Global Prednisone Sales Growth (2013-2018)
10.3.2 Global Prednisone Price (2013-2018)
10.4 Others Sales Growth and Price
10.4.1 Global Others Sales Growth (2013-2018)
10.4.2 Global Others Price (2013-2018)
11 Global Duchenne Muscular Dystrophy Market Segment by Application
11.1 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2013-2018)
11.2 Male Sales Growth (2013-2018)
11.3 Female Sales Growth (2013-2018)
12 Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.1 Global Duchenne Muscular Dystrophy Sales, Revenue and Growth Rate (2018-2023)
12.2 Duchenne Muscular Dystrophy Market Forecast by Regions (2018-2023)
12.2.1 North America Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.2 Europe Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.3 Asia-Pacific Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.4 South America Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.5 Middle East and Africa Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.3 Duchenne Muscular Dystrophy Market Forecast by Type (2018-2023)
12.3.1 Global Duchenne Muscular Dystrophy Sales Forecast by Type (2018-2023)
12.3.2 Global Duchenne Muscular Dystrophy Market Share Forecast by Type (2018-2023)
12.4 Duchenne Muscular Dystrophy Market Forecast by Application (2018-2023)
12.4.1 Global Duchenne Muscular Dystrophy Sales Forecast by Application (2018-2023)
12.4.2 Global Duchenne Muscular Dystrophy Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report